The role of health technology assessment bodies in shaping drug development by Ciani O, Jommi C

Get full text

The Impasse on Overall Survival in Oncology Reimbursement Decision-Making: How Can We Resolve This? by Lux MP, Ciani O, Dunlop WCN, Ferris A, Friedlander M

Get full text

Protocol for the development of SPIRIT and CONSORT extensions for randomised controlled trials with surrogate primary endpoints: SPIRIT-SURROGATE and CONSORT-SURROGATE by Manyara, AM, Davies, P, Stewart, D, Weir, CJ, Young, A, Butcher, NJ, Bujkiewicz, S, Chan, A-W, Collins, GS, Dawoud, D, Offringa, M, Ouwens, M, Ross, JS, Taylor, RS, Ciani, O

Definitions, acceptability, limitations, and guidance in the use and reporting of surrogate end points in trials: a scoping review by Manyara, AM, Davies, P, Stewart, D, Weir, CJ, Young, AE, Wells, V, Blazeby, J, Butcher, NJ, Bujkiewicz, S, Chan, A-W, Collins, GS, Dawoud, D, Offringa, M, Ouwens, M, Ross, JS, Taylor, RS, Ciani, O

A framework for the definition and interpretation of the use of surrogate endpoints in interventional trials by Ciani, O, Manyara, AM, Davies, P, Stewart, D, Weir, CJ, Young, AE, Blazeby, J, Butcher, NJ, Bujkiewicz, S, Chan, A-W, Dawoud, D, Offringa, M, Ouwens, M, Hróbjartssson, A, Amstutz, A, Bertolaccini, L, Bruno, VD, Devane, D, Faria, CDCM, Gilbert, PB, Harris, R, Lassere, M, Marinelli, L, Markham, S, Powers, JH, Rezaei, Y, Richert, L, Schwendicke, F, Tereshchenko, LG, Thoma, A, Turan, A, Worrall, A, Christensen, R, Collins, GS, Ross, JS, Taylor, RS